Urinary incontinence is a common disease that affects women’s quality of life. According to statistics, the global prevalence rate is close to 50%, and the prevalence rate of our population is comparable, half of which is stress incontinence. In the female population, 23% to 45% have different degrees of incontinence, about 7% have obvious incontinence symptoms, of which about 50% are stress incontinence, followed by mixed and urge incontinence. Stress incontinence refers to the involuntary leakage of urine from the urethra when abdominal pressure is increased by coughing, sneezing or exercise. Symptoms are involuntary leakage of urine on increased abdominal pressure such as coughing, sneezing, or laughing. Signs are observable as urine, involuntarily flowing out of the urethra when abdominal pressure is increased. Risk factors for stress incontinence are related to age, childbearing, pelvic organ prolapse, obesity, and genetics. There may also be a relationship with estrogen, hysterectomy, smoking, and intense physical activity. Diagnosis is based on history and physical examination. And ultrasound examination of urinary diary, urine routine, urinary tract, gynecology and residual urine is recommended. Clinically, it is divided into 3 degrees. Mild: no urinary incontinence during general activities and at night, occasional incontinence when abdominal pressure increases, no need to wear a pad. Moderate: frequent incontinence with increased abdominal pressure and standing up activities, need to wear a pad to live. Severe: urinary incontinence when standing up or lying down, seriously affecting the patient’s life and social activities. Non-surgical treatment I. Conservative treatment 1, weight control Obese patients should control their weight 2, pelvic floor muscle training Methods: continuous contraction of the pelvic floor muscles (lifting the anus movement) for 2-6 seconds, relaxation and rest for 2-6 seconds, and so on for 10-15 times as a group. 3~8 groups per day for more than 8 weeks or longer. 3, biofeedback medication ① 5-hydroxytryptamine and norepinephrine reuptake inhibitors: duloxetine 40mg, bid, 3 months ② estrogen postmenopausal vaginal topical use Surgical treatment For non-surgical treatment is ineffective in patients with moderate and severe feasible tension-free urethral sling surgery.